Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

May 28, 2014

Primary Completion Date

August 11, 2016

Study Completion Date

October 31, 2016

Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
DRUG

Ciprofloxacin dispersion for inhalation

DRUG

Placebo

Trial Locations (95)

Unknown

Phoenix

Scottsdale

Sacramento

San Diego

Torrance

Danbury

Miami

Orlando

Winter Park

Decatur

Duluth

Port Huron

Omaha

Lebanon

Summit

Albuquerque

New York

Chapel Hill

Columbus

Philadelphia

Rock Hill

Spartanburg

Tyler

Seattle

Milwaukee

Greenslopes

Adelaide

Nedlands

Perth

Vancouver

Toronto

Windsor

Saint-Jérôme

Créteil

Grenoble

Nice

Pessac

Rouen

Toulouse

Kutaisi

Tbilisi

Budapest

Nyíregyháza

Székesfehérvár

Törökbálint

Jerusalem

Petah Tikva

Ramat Gan

Tel Aviv

Avellino

Napoli

Parma

Pisa

San Gerardo

Terni

Trieste

Otahuhu

Hamilton

Tauranga

Jesus Maria

La Victoria

Pueblo Libre

San Juan de Miraflores

Bialystok

Krakow

Ruda Śląska

Warsaw

Arad

Bucharest

Cluj-Napoca

Craiova

Iași

Belgrade

Knez Selo

Kragujevac

Sremska Kamenica

Suwon

Daegu

Seoul

A Coruña

Barcelona

Lleida

Valencia

Stockton-on-Trees

Wigan

Cambridge

Colchester

Cottingham

Lancaster

Leeds

London

Manchester

North Sheilds

Southampton

Telford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Grifols Therapeutics LLC

INDUSTRY

lead

Aradigm Corporation

INDUSTRY

NCT02104245 - Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4) | Biotech Hunter | Biotech Hunter